MitoxantronePrednisoneVincristineAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinCytarabineAnthraquinonesAntineoplastic AgentsPrednisoloneGlucocorticoidsTreatment OutcomeRemission InductionEtoposideDrug Administration ScheduleMelphalanProcarbazineATP-Binding Cassette TransportersLymphoma, Non-HodgkinDrug Resistance, NeoplasmAntibodies, Monoclonal, Murine-DerivedVidarabineImmunosuppressive AgentsMechlorethamineChlorambucilDaunorubicinAzathioprineTaxoidsDrug Resistance, MultipleEstramustineDrug Therapy, CombinationBleomycinAnti-Inflammatory AgentsMethotrexateSurvival AnalysisProstatic NeoplasmsCyclosporinsDisease-Free SurvivalSurvival RateIdarubicinP-GlycoproteinAmsacrineNeoplasm ProteinsHodgkin DiseaseLymphoma, FollicularDrug EvaluationRazoxaneCyclosporineTopoisomerase InhibitorsRecurrenceDose-Response Relationship, DrugIntercalating AgentsColor TherapyVinblastineFollow-Up StudiesLeukemia, MyeloidCombined Modality TherapyTopotecanCardiotoxinsSalvage TherapyMultiple MyelomaMethylprednisoloneHematologic DiseasesLeukemia, Myeloid, AcuteOrchiectomyTime FactorsLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-LymphomaDNA Topoisomerases, Type IIPalliative CareDrug ResistanceProstate-Specific AntigenMycophenolic Acid